Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the ...

Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. The consensus EPS Estimate is $7.91 and the consensus Revenue Estimate ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

Pfizer Inc (PFE) reports a 32% operational revenue growth and raises full-year guidance, despite challenges in COVID-19 ...

We think the market is overly bearish about Pfizer’s ability to right the ship, and we see shares as undervalued.

Despite today's fall in Pfizer's share price, it beat my and Wall Street analysts' expectations for Q3 by a large margin. See ...

The company’s updated guidance for revenue includes approximately $10.5B in anticipated revenues for Comirnaty and Paxlovid, ...

Pfizer PFE reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 ...

Pfizer (PFE) stock gained after the company beat estimates with its Q3 2024 financials and raised its full-year guidance ...

Pfizer (NYSE: PFE) shares climbed around 2% in premarket trading Tuesday after the pharma giant raised earnings and revenue ...